Sabrina Serani

Vote on the latest breakthroughs in renal and bladder cancer at ESMO 2025, featuring pivotal late-breaking abstracts.

The FDA approves lurbinectedin and atezolizumab for first-line maintenance in extensive-stage small cell lung cancer, significantly enhancing survival rates.

FDA fast tracks ETX-636, a promising treatment for advanced breast cancer with PIK3CA mutations, aiming to improve patient outcomes.

FDA accepts T-DXd for neoadjuvant HER2-positive breast cancer treatment, promising improved outcomes and safety for high-risk patients.

Discover the most anticipated late-breaking abstracts in gastrointestinal cancers at ESMO 2025 and influence the conversation in oncology research.

Dr Sarah Premji discusses advancements in breast cancer treatment, emphasizing community trials, personalized therapies, and how to address unmet patient needs.

Umoja Biopharma's UB-VV111 receives FDA fast track designation, advancing CAR T cell therapy for relapsed/refractory B-cell malignancies.

Explore upcoming PDUFA action dates for innovative oncology treatments, including promising therapies for hard-to-treat cancers in late 2025.

A groundbreaking trial reveals trastuzumab deruxtecan significantly improves survival in high-risk HER2-positive breast cancer patients post-neoadjuvant therapy.

FDA approves imlunestrant for advanced breast cancer, enhancing treatment options for patients with ESR1 mutations through innovative genomic profiling.

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective heart rhythm monitoring.

The FDA approves imlunestrant, offering a new oral treatment option for advanced ER-positive breast cancer, enhancing patient outcomes and management.

New clinical data reveals stenoparib significantly extends survival in advanced platinum-resistant ovarian cancer, offering hope for patients with limited options.

Iberdomide combined with daratumumab and dexamethasone shows promising results in improving MRD negativity rates for relapsed multiple myeloma patients.

IMNN-001 shows promising results in enhancing the tumor microenvironment and improving survival rates in advanced ovarian cancer treatment.

FDA prioritizes review of T-DXd for first-line HER2-positive breast cancer treatment, showcasing significant survival benefits in recent studies.

Discover the latest advancements in lymphoma treatment, including innovative therapies and personalized medicine, enhancing patient outcomes and quality of life.

The evERA study reveals promising results for giredestrant in treating advanced ER-positive breast cancer, enhancing progression-free survival for patients.

Research explores innovative treatments for high-risk smoldering multiple myeloma, highlighting promising results from the bispecific antibody linvoseltamab.

The FDA approves a new diagnostic kit for identifying acute leukemia patients eligible for the groundbreaking Menin inhibitor, revumenib.

New NCCN guidelines recommend lurbinectedin with atezolizumab as a first-line maintenance therapy for extensive-stage small cell lung cancer, enhancing treatment options.

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP inhibitors, and innovative PROTAC therapies.

MNV-201 gains FDA fast track designation for myelodysplastic syndromes, promising expedited development and potential breakthroughs in treatment.

A new treatment combination shows promise in extending progression-free survival for advanced prostate cancer patients, highlighting innovative cancer therapies.

New study reveals plixorafenib shows significant clinical benefits for thyroid cancer patients with BRAF mutations, offering hope for targeted therapies.

The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma.

The FDA fast-tracks CRB-701, an innovative ADC for advanced head and neck cancer, showing promising efficacy and safety in ongoing trials.

Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic malignancies and solid tumors.

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic strategies for this aggressive disease.